TNF and inflammatory bowel disease: This systematic review included 307 patients in the vedolizumab‐treated group, 490 patients in the anti‐TNF treatment group, and 535 patients who did not receive preoperative biological therapy; preoperative vedolizumab treatment was not associated with an increased risk of postoperative complications compared to preoperative anti‐TNF treatment or no biological therapy in IBD patients.32 Yung et al reported that the risk of postoperative complications was not significantly different between preoperative vedolizumab and anti‐TNF in IBD patients.